No child left behind, literacy challenges ahead: a focus on the Philippines
Frontiers in Education · 05.06.2024 · 9
DOI: 10.3389/feduc.2024.1349307 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Education, online erschienen am 05.06.2024. Verfasst von Al Ryanne Gabonada Gatcho und 2 weiteren Autor:innen. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The Sustainable Development Goal 4 has commenced a global mandate to provide equitable access to quality education for everyone. In the Philippines, SDG 4 inaugurates the No Child Left Behind (NCLB) Policy. This brief argues that while the NCLB has ensured equal access to quality literacy education, it poses socioeconomic-based challenges, declining rate of parental involvement in their children’s schooling, overemphasis on standardized tests, and the lack of community involvement towards literacy programs. The Holistic Literacy Enhancement Program (HLEP) is proposed in this paper to help address these challenges to NCLB. HLEP presents policy implications that could assist the NCLB in more efficient and effective implementation: equitable resource allocation, parental and community engagement, and culturally and linguistically relevant assessment tools.
Zitieren
APA
Gatcho, A. R. G., Manuel, J. P. G., & Hajan, B. H. (2024). No child left behind, literacy challenges ahead: a focus on the Philippines. Frontiers in Education, 9. https://doi.org/10.3389/feduc.2024.1349307
Vancouver
Gatcho ARG, Manuel JPG, Hajan BH. No child left behind, literacy challenges ahead: a focus on the Philippines. Frontiers in Education. 2024;9. doi:10.3389/feduc.2024.1349307
BibTeX
@article{Gatcho2024,
author = {Gatcho, Al Ryanne Gabonada and Manuel, Jeremiah Paul Giron and Hajan, Bonjovi Hassan},
title = {No child left behind, literacy challenges ahead: a focus on the Philippines},
journal = {Frontiers in Education},
year = {2024},
volume = {9},
doi = {10.3389/feduc.2024.1349307}
}
EUVIMED